PMID- 25327159 OWN - NLM STAT- MEDLINE DCOM- 20150311 LR - 20170112 IS - 0392-856X (Print) IS - 0392-856X (Linking) VI - 32 IP - 6 DP - 2014 Nov-Dec TI - Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. PG - 942-8 AB - OBJECTIVES: The aim of this paper is to assess the usefulness of measuring serum levels of adalimumab (ADL) and anti-ADL antibodies in 57 patients with rheumatoid arthritis (RA) treated with ADL for at least 3 months in daily practice. METHODS: All patients received concomitant disease-modifying anti-rheumatic drug (DMARD). Receiver-operator characteristics (ROC) analysis was used to obtain the cut-off value of ADL for low disease activity (DAS28-ESR 3.2 showed significantly better SDAI score, higher serum concentrations of ADL and none of them showed anti-ADL antibodies. The cut-off of serum level of ADL for DAS28 <3.2 was 4.3 mg/L. According to serum levels of ADL, patients were grouped into group 1 (low level) <5.5 mg/L, group 2 (medium level) 5.5-11.3 mg/L and group 3 (high level) >11.3 mg/L. Patients in the medium group were closed to clinical remission (median DAS28 2.7) and patients in the high group were on clinical remission (DAS28 2.1). CONCLUSIONS: Serum levels of ADL should be maintained >4.3 mg/L. In patients with ADL levels >11.3 mg/L, a decrease of the dose of ADL or an increase in the interval between doses may be planned. The presence of anti-ADL antibodies was associated with a loss of clinical efficacy of ADL. FAU - Rosas, Jose AU - Rosas J AD - Department of Rheumatology, Marina Baixa Hospital, Villajoyosa, Alicante, Spain. j.rosas.gs@gmail.com. FAU - Llinares-Tello, Francisca AU - Llinares-Tello F FAU - de la Torre, Inmaculada AU - de la Torre I FAU - Santos-Ramirez, Carlos AU - Santos-Ramirez C FAU - Senabre-Gallego, Jose Miguel AU - Senabre-Gallego JM FAU - Valor, Lara AU - Valor L FAU - Barber-Valles, Xavier AU - Barber-Valles X FAU - Hernandez-Florez, Diana AU - Hernandez-Florez D FAU - Santos-Soler, Gregorio AU - Santos-Soler G FAU - Salas-Heredia, Esteban AU - Salas-Heredia E FAU - Carreno, Luis AU - Carreno L CN - AIRE-MB Group LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20141020 PL - Italy TA - Clin Exp Rheumatol JT - Clinical and experimental rheumatology JID - 8308521 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antirheumatic Agents) RN - 0 (Biomarkers) RN - FYS6T7F842 (Adalimumab) SB - IM MH - Adalimumab MH - Aged MH - Antibodies, Monoclonal, Humanized/administration & dosage/*blood/immunology MH - Antirheumatic Agents/administration & dosage/*blood/immunology MH - Area Under Curve MH - Arthritis, Rheumatoid/blood/diagnosis/*drug therapy/immunology MH - Biomarkers/blood MH - Cross-Sectional Studies MH - *Drug Monitoring MH - Female MH - Humans MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - ROC Curve MH - Spain MH - Time Factors MH - Treatment Outcome FIR - Gomez de Salazar, Jose Rosas IR - Gomez de Salazar JR FIR - Senabre Gallego, Jose Miguel IR - Senabre Gallego JM FIR - Soler, Gregorio Santos IR - Soler GS FIR - Heredia, Esteban Salas IR - Heredia ES FIR - Perez, Catalina Cano IR - Perez CC FIR - Pons Bas, Ana IR - Pons Bas A FIR - Lorente Betoret, Marisa IR - Lorente Betoret M FIR - Llinares Tello, Francisca IR - Llinares Tello F FIR - Molina Garcia, Juan IR - Molina Garcia J FIR - Ramirez, Carlos Santos IR - Ramirez CS FIR - Ortega Castro, Rafaela IR - Ortega Castro R FIR - Barber Valles, Xavier IR - Barber Valles X FIR - Sanchez Barrioluego, Mabel IR - Sanchez Barrioluego M FIR - Garcia-Carrasco, Mario IR - Garcia-Carrasco M EDAT- 2014/10/21 06:00 MHDA- 2015/03/12 06:00 CRDT- 2014/10/21 06:00 PHST- 2014/03/09 00:00 [received] PHST- 2014/06/24 00:00 [accepted] PHST- 2014/10/21 06:00 [entrez] PHST- 2014/10/21 06:00 [pubmed] PHST- 2015/03/12 06:00 [medline] AID - 8069 [pii] PST - ppublish SO - Clin Exp Rheumatol. 2014 Nov-Dec;32(6):942-8. Epub 2014 Oct 20.